QuickView: ZoptEC moving ahead
Aeterna Zentaris reported at the 2014 ASCO that 158 patients have been randomised as of 26 May 2014 in the zoptarelin doxorubicin in endometrial cancer (ZoptEC) Phase III trial, moving closer to the first interim analysis scheduled to take place in mid-2015. It has cash and cash equivalents of $45.8m at the end of March 2014, which should be enough to support its operation into mid-2015 when the first interim analysis of ZoptEC takes place.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.